Cargando…
An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
BNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech, New York, NY, USA), is one of the most effective COVID-19 vaccines and has been approved by more than 130 countries worldwide. However, several studies have reported that the COVID-19 vaccine shows high interpersonal variability in terms o...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029840/ https://www.ncbi.nlm.nih.gov/pubmed/35455312 http://dx.doi.org/10.3390/vaccines10040563 |
_version_ | 1784691998320492544 |
---|---|
author | Khor, Seik-Soon Omae, Yosuke Takeuchi, Junko S. Fukunaga, Ami Yamamoto, Shohei Tanaka, Akihito Matsuda, Kouki Kimura, Moto Maeda, Kenji Ueda, Gohzoh Mizoue, Tetsuya Ujiie, Mugen Mitsuya, Hiroaki Ohmagari, Norio Sugiura, Wataru Tokunaga, Katsushi |
author_facet | Khor, Seik-Soon Omae, Yosuke Takeuchi, Junko S. Fukunaga, Ami Yamamoto, Shohei Tanaka, Akihito Matsuda, Kouki Kimura, Moto Maeda, Kenji Ueda, Gohzoh Mizoue, Tetsuya Ujiie, Mugen Mitsuya, Hiroaki Ohmagari, Norio Sugiura, Wataru Tokunaga, Katsushi |
author_sort | Khor, Seik-Soon |
collection | PubMed |
description | BNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech, New York, NY, USA), is one of the most effective COVID-19 vaccines and has been approved by more than 130 countries worldwide. However, several studies have reported that the COVID-19 vaccine shows high interpersonal variability in terms of humoral and cellular responses, such as those with respect to SARS-CoV-2 spike protein immunoglobulin (Ig)G, IgA, IgM, neutralizing antibodies, and CD4(+) and CD8(+) T cells. The objective of this study is to investigate the kinetic changes in anti-SARS-CoV-2 spike IgG (IgG-S) profiles and adverse reactions and their associations with HLA profiles (HLA-A, -C, -B, -DRB1, -DQA1, -DQB1, -DPA1 and -DPB1) among 100 hospital workers from the Center Hospital of the National Center for Global Health and Medicine (NCGM), Tokyo, Japan. DQA1*03:03:01 (p = 0.017; Odd ratio (OR) 2.80, 95%confidence interval (CI) 1.05–7.25) was significantly associated with higher IgG-S production after two doses of BNT162b2, while DQB1*06:01:01:01 (p = 0.028, OR 0.27, 95%CI 0.05–0.94) was significantly associated with IgG-S declines after two doses of BNT162b2. No HLA alleles were significantly associated with either local symptoms or fever. However, C*12:02:02 (p = 0.058; OR 0.42, 95%CI 0.15–1.16), B*52:01:01 (p = 0.031; OR 0.38, 95%CI 0.14–1.03), DQA1*03:02:01 (p = 0.028; OR 0.39, 95%CI 0.15–1.00) and DPB1*02:01:02 (p = 0.024; OR 0.45, 95%CI 0.21–0.97) appeared significantly associated with protection against systemic symptoms after two doses of BNT162b2 vaccination. Further studies with larger sample sizes are clearly warranted to determine HLA allele associations with the production and long-term sustainability of IgG-S after COVID-19 vaccination. |
format | Online Article Text |
id | pubmed-9029840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90298402022-04-23 An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine Khor, Seik-Soon Omae, Yosuke Takeuchi, Junko S. Fukunaga, Ami Yamamoto, Shohei Tanaka, Akihito Matsuda, Kouki Kimura, Moto Maeda, Kenji Ueda, Gohzoh Mizoue, Tetsuya Ujiie, Mugen Mitsuya, Hiroaki Ohmagari, Norio Sugiura, Wataru Tokunaga, Katsushi Vaccines (Basel) Article BNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech, New York, NY, USA), is one of the most effective COVID-19 vaccines and has been approved by more than 130 countries worldwide. However, several studies have reported that the COVID-19 vaccine shows high interpersonal variability in terms of humoral and cellular responses, such as those with respect to SARS-CoV-2 spike protein immunoglobulin (Ig)G, IgA, IgM, neutralizing antibodies, and CD4(+) and CD8(+) T cells. The objective of this study is to investigate the kinetic changes in anti-SARS-CoV-2 spike IgG (IgG-S) profiles and adverse reactions and their associations with HLA profiles (HLA-A, -C, -B, -DRB1, -DQA1, -DQB1, -DPA1 and -DPB1) among 100 hospital workers from the Center Hospital of the National Center for Global Health and Medicine (NCGM), Tokyo, Japan. DQA1*03:03:01 (p = 0.017; Odd ratio (OR) 2.80, 95%confidence interval (CI) 1.05–7.25) was significantly associated with higher IgG-S production after two doses of BNT162b2, while DQB1*06:01:01:01 (p = 0.028, OR 0.27, 95%CI 0.05–0.94) was significantly associated with IgG-S declines after two doses of BNT162b2. No HLA alleles were significantly associated with either local symptoms or fever. However, C*12:02:02 (p = 0.058; OR 0.42, 95%CI 0.15–1.16), B*52:01:01 (p = 0.031; OR 0.38, 95%CI 0.14–1.03), DQA1*03:02:01 (p = 0.028; OR 0.39, 95%CI 0.15–1.00) and DPB1*02:01:02 (p = 0.024; OR 0.45, 95%CI 0.21–0.97) appeared significantly associated with protection against systemic symptoms after two doses of BNT162b2 vaccination. Further studies with larger sample sizes are clearly warranted to determine HLA allele associations with the production and long-term sustainability of IgG-S after COVID-19 vaccination. MDPI 2022-04-05 /pmc/articles/PMC9029840/ /pubmed/35455312 http://dx.doi.org/10.3390/vaccines10040563 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Khor, Seik-Soon Omae, Yosuke Takeuchi, Junko S. Fukunaga, Ami Yamamoto, Shohei Tanaka, Akihito Matsuda, Kouki Kimura, Moto Maeda, Kenji Ueda, Gohzoh Mizoue, Tetsuya Ujiie, Mugen Mitsuya, Hiroaki Ohmagari, Norio Sugiura, Wataru Tokunaga, Katsushi An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine |
title | An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine |
title_full | An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine |
title_fullStr | An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine |
title_full_unstemmed | An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine |
title_short | An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine |
title_sort | association study of hla with the kinetics of sars-cov-2 spike specific igg antibody responses to bnt162b2 mrna vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029840/ https://www.ncbi.nlm.nih.gov/pubmed/35455312 http://dx.doi.org/10.3390/vaccines10040563 |
work_keys_str_mv | AT khorseiksoon anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT omaeyosuke anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT takeuchijunkos anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT fukunagaami anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT yamamotoshohei anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT tanakaakihito anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT matsudakouki anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT kimuramoto anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT maedakenji anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT uedagohzoh anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT mizouetetsuya anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT ujiiemugen anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT mitsuyahiroaki anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT ohmagarinorio anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT sugiurawataru anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT tokunagakatsushi anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT khorseiksoon associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT omaeyosuke associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT takeuchijunkos associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT fukunagaami associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT yamamotoshohei associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT tanakaakihito associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT matsudakouki associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT kimuramoto associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT maedakenji associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT uedagohzoh associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT mizouetetsuya associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT ujiiemugen associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT mitsuyahiroaki associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT ohmagarinorio associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT sugiurawataru associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT tokunagakatsushi associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine |